BVCF, formerly known as BioVeda China, it provides growth capital to China-based companies operating in life sciences and healthcare industries. These include biotechnology, agriculture and pharmaceuticals sectors. In 2005, BVCF spun off from Singapore-based BioVeda Capital and now operates as an independent entity from BioVeda Capital.BVCF looks to invest in Chinese SMEs with international growth potential and seeks to increase the value of its portfolio companies through the provision of industry knowledge. While BVCF primarily takes significant minority positions in its investee companies, it will also take controlling positions selectively. It seeks to exit its investments within three to five years via IPO or trade sale.
Growth
5 funds found in our dataset.
Built for investment teams that need to move faster.
Intelligently process data room financials, generate auditable analyses, and export IC-ready deliverables.